We’re pleased to share that the Hongkang Biomedical Headquarters & Production Base Project (Land Plot No. Hangqiantang Gongchu [2025] No.24) was publicly announced by the Hangzhou Municipal Bureau of Planning and Natural Resources on January 27, 2026. Situated in Zhejiang’s China Pharmaceutical Port Town, this initiative marks a pivotal step in our global strategy for smart, sustainable hard capsule production.

• Total GFA of 37,952.77 ㎡, equipped with 32 fully automated production lines
• End-to-end unmanned operations, covering gelatin, HPMC, pullulan polysaccharide and targeted hard capsules
• Scheduled for mass production in 2028, with an annual capacity exceeding 400 billion units post-commissioning

As a leader in China’s hard capsule industry—with Zhejiang contributing 42% of the nation’s total output (industry data)—Hongkang is dedicated to building a world-class smart and green production hub. This "lights-out factory" will boost production efficiency while elevating sustainability, aligning with global ESG priorities in the pharmaceutical sector.